文献速递妇科

系统综述:肿瘤相关抗原自身抗体与卵巢癌早期检测

Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
PubMed 文献 · Gynecol Oncol · 2017-08-08

本系统综述纳入29项研究、85种自身抗体,总结单个自身抗体及抗体组合对卵巢癌的诊断性能。部分自身抗体在高特异度下显示较高灵敏度,但组织学与分期数据稀疏;作者认为需大规模前瞻性研究进行发现与验证。

要点

  • RhoGDI-AAb灵敏度89.5%、特异度80%;TUBA1C-AAb灵敏度89%、特异度75%。
  • HOXA7-AAb检测中分化卵巢肿瘤:特异度100%时灵敏度66.7%。
  • IL8-AAb检测I-II期卵巢癌:特异度98%时灵敏度65.5%。

核心结论

  • 卵巢癌早期检测的自身抗体是新兴领域,需考虑组织学与分期的大规模前瞻性研究进行发现与验证。
  • 现有数据提示自身抗体组合可能最终达到足够的诊断区分度,作为现有标志物和经阴道超声的补充实现更早检测。

研究设计与样本

  • 系统综述,共纳入29项研究、85种自身抗体。
  • 27项研究在现患病例与无癌对照中进行,2项研究纳入诊断前样本。
  • 多数研究为假设驱动、评估针对目标肿瘤相关抗原的自身抗体;10项研究使用血清学表达克隆(SEREX)和核酸可编程蛋白阵列(NAPPA)等筛选方法。

主要发现

  • 单个自身抗体最高灵敏度为RhoGDI-AAb(89.5%)和TUBA1C-AAb(89%),但特异度相对较低(分别为80%和75%)。
  • HOXA7-AAb检测中分化卵巢肿瘤在100%特异度下灵敏度为66.7%。
  • IL8-AAb检测I-II期卵巢癌在98%特异度下灵敏度为65.5%。
  • 11种自身抗体组合(ICAM3、CTAG2、p53、STYXL1、PVR、POMC、NUDT11、TRIM39、UHMK1、KSR1和NXF3)在至少2种自身抗体高于95%特异度阈值时,对浆液性卵巢癌在98%特异度下灵敏度为45%。
  • 本综述识别的自身抗体中有12种在超过一项研究中被研究;按肿瘤组织学和诊断时分期的诊断区分度数据稀疏;有限数据提示部分自身抗体标志物与CA125和HE4等标志物联合时可改善诊断区分度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 按肿瘤组织学和诊断时分期的诊断区分度数据稀疏。
  • 有限数据提示部分自身抗体标志物与CA125和HE4等标志物联合时可改善诊断区分度。
  • 作者结论指出需考虑组织学与分期的大规模前瞻性研究进行发现与验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tumor-associated autoantibodies (AAbs), produced as an immune response to tumor-associated antigens (TAAs), are a novel pathway of early detection markers. METHODS: We conducted a systematic review on AAbs and ovarian cancer to summarize the diagnostic performance of individual AAbs and AAb panels. A total of 29 studies including 85 AAbs were included; 27 of the studies were conducted in prevalent cases and cancer-free controls and 2 investigations included pre-diagnosis samples. The majority of studies were hypothesis-driven, evaluating AAbs to target TAAs; 10 studies used screening approaches such as serological expression cloning (SEREX) and nucleic acid-programmable protein arrays (NAPPA). RESULTS: The highest sensitivities for individual AAbs were reported for RhoGDI-AAbs (89.5%) and TUBA1C-AAbs (89%); however, specificity levels were relatively low (80% and 75%, respectively). High sensitivities at high specificities were reported for HOXA7-AAbs for detection of moderately differentiated ovarian tumors (66.7% sensitivity at 100% specificity) and IL8-AAbs in stage I-II ovarian cancer (65.5% sensitivity at 98% specificity). A panel of 11 AAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) provided 45% sensitivity at 98% specificity for serous ovarian cancer, when at least 2 AAbs were above a threshold of 95% specificity. Twelve of the AAbs identified in this review were investigated in more than one study. Data on diagnostic discrimination by tumor histology and stage at diagnosis are sparse. Limited data suggest select AAb markers improve diagnostic discrimination when combined with markers such as CA125 and HE4. CONCLUSIONS: AAbs for ovarian cancer early detection is an emerging area, and large-scale, prospective investigations considering histology and stage are required for discovery and validation. However, data to date suggests panels of AAbs may eventually reach sufficient diagnostic discrimination to allow earlier detection of disease as a complement to existing markers and transvaginal ultrasound.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Fortner RT, Damms-Machado A, Kaaks R, et al. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol Oncol. 2017. PMID: 28800944. doi:10.1016/j.ygyno.2017.07.138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。